Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Achaogen Inc AKAOQ

Healthcare Biotechnology
"Achaogen Inc is a biopharmaceutical company developing novel antibacterial treatments against multi-drug resistant gram-negative infections. The company is researching and developing on its product plazomicin used for the treatment of serious bacterial infections. It's another antibacterial candidate, C-Scape treats patients with urinary tract infections. All of the company's revenue is... see more

Recent & Breaking News (OTCPK:AKAOQ)

Achaogen Announces Closing of Public Offering

GlobeNewswire May 31, 2017

Achaogen Announces Multiple Plazomicin Presentations at ASM Microbe 2017 Annual Meeting

GlobeNewswire May 26, 2017

Achaogen Announces Pricing of Public Offering of Common Stock

GlobeNewswire May 25, 2017

Plazomicin Granted FDA Breakthrough Therapy Designation

GlobeNewswire May 23, 2017

Achaogen Announces Proposed Public Offering of Common Stock

GlobeNewswire May 23, 2017

Achaogen Reports First Quarter 2017 Financial Results and Provides Corporate Update

GlobeNewswire May 8, 2017

Investor Network: Achaogen, Inc. to Host Earnings Call

Accesswire May 8, 2017

Achaogen Receives Investment from the Bill & Melinda Gates Foundation to Develop Antibodies Against Gram-Negative Bacteria

GlobeNewswire May 5, 2017

Achaogen to Host Conference Call and Webcast of First Quarter 2017 Financial Results on May 8, 2017

GlobeNewswire May 1, 2017

Achaogen Unveils Data Highlighting the Effectiveness of Plazomicin Against MDR Gram-Negative Bacteria at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

GlobeNewswire April 24, 2017

Achaogen Announces Multiple Plazomicin Presentations at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

GlobeNewswire April 13, 2017

Achaogen to Present at Needham & Company’s 16th Annual Healthcare Conference

GlobeNewswire March 30, 2017

Achaogen Announces Data on Epidemiological Trends of Carbapenem-Resistant Enterobacteriaceae at SHEA Spring 2017 Conference

GlobeNewswire March 29, 2017

12 Biggest Mid-Day Losers For Wednesday

Benzinga.com  March 15, 2017

20 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  March 15, 2017

Achaogen Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

GlobeNewswire March 14, 2017

Achaogen to Host Conference Call and Webcast of Fourth Quarter and Year 2016 Financial Results on March 14, 2017

GlobeNewswire March 6, 2017

Achaogen to Present at the Cowen and Company 37th Annual Health Care Conference

GlobeNewswire March 2, 2017

Achaogen Highlights Emerging Pipeline of Antibacterials Including a new Orally-Administered Antibiotic Clinical Candidate at Company's R&D Day

GlobeNewswire March 1, 2017

Achaogen Announces New Employment Inducement Grants

GlobeNewswire February 28, 2017